The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

Abstract Background The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM). This regimen modestly prolongs overall survival, also if, in light of the still dismal prognosis, further improvements are desperately needed...

Full description

Bibliographic Details
Main Authors: Claudio Festuccia, Andrea Mancini, Alessandro Colapietro, Giovanni Luca Gravina, Flora Vitale, Francesco Marampon, Simona Delle Monache, Simona Pompili, Loredana Cristiano, Antonella Vetuschi, Vincenzo Tombolini, Yi Chen, Thomas Mehrling
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Journal of Hematology & Oncology
Subjects:
Glioblastoma
Bendamustine
Vorinostat
Tinostamustine
Radio sensitivity
Online Access:http://link.springer.com/article/10.1186/s13045-018-0576-6

Internet

http://link.springer.com/article/10.1186/s13045-018-0576-6

Similar Items